Vasopeptidase inhibition for blood pressure control: Emerging experience

Current Pharmaceutical Design

Volumn 11, Issue 25, 2005, Pages 3293-3299

  Quaschning, Thomas ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Angiotensin; Bradykinin; Endothelin; Endothelium; Hypertension; Nitric oxide

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CANDOXATRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENKEPHALINASE INHIBITOR; LISINOPRIL; OMAPATRILAT; PLACEBO; RAMIPRIL; SAMAPTRILAT; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FLUSHING; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; SIDE EFFECT; SYSTOLIC HYPERTENSION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; NEPRILYSIN; PROTEASE INHIBITORS;

EID: 24944538873     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774424708     Document Type: Review

References (70)

1. Cheung BM, Lau CP. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Br J Pharmacol 1999; 47: 179-187.
2. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effects of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
3. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-684.
4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunciton after myocardial infarction. Results of the survival and ventriuclar enlargement trial. The SAVE investigators. N Eng J Med 1992; 327: 669-677.
5. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term. Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332: 80-85.
6. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178.
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
8. Scholkens BA. Kinins in the cardiovascular system. Immunopharmacology 1996; 33: 209-216.
9. Zhang X, Xie YW, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997; 95: 176-182.
10. Wiemer G, Scholkens BA, Becker RH, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-563.
11. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3: 145-151.
12. Murphy LJ, Corder R, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c- terminal fragment from big endothelin-1. Br J Pharmacol 1994; 113: 137-142.
13. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993; 11: 407-416.
14. Molinaro G, Rouleau JL, Adam A. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr Opin Pharmacol 2002; 2: 131-141.
15. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Lücher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001; 104: 1856-1862.
16. Kolloch R, Offers E. Vasopeptidase inhibition. A new mechanism of action for the treatment of hypertension and cardiac insufficiency. Internist (Berl) 2001; 42: 290-296.
17. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 358: 1525-1532.
18. Ruschitzka F, Corti R, Quaschning T, Hermann M, Lüscher TF. Vasopeptidase inhibitors-concepts and evidence. Nephrol Dial Transplant 2001; 16: 1532-1535.
19. Fournie-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB, et al. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci USA 1994; 91: 4072-4076.
20. Mitchell GF, Block AJ, Hartley LH, Tardiff JC, Rouleau JL, Pfeffer MA, et al. The vasopeptidase inhibitor omapatrilat has a favorable pressure-independent effect on conduit vessel stiffness in patients with congestive heart failure. Circulation 1999; 100(Suppl 1): 1-646.
21. Dendorfer A, Dominiak P. Vasopeptidase inhibition as a new concept in antihypertensive therapy. Kidney Blood Press Res. 2000; 23: 178-179.
22. Wensel UO, Wolf G, Helmchen U, Stahl RAK. Effects of the vasopeptidase inhibitor omapatrilat in rats with 2-kidney 1-clip (2K1C) Goldblatt hypertension. J Am Soc Nephrol 2000; 11: 343.
23. Tikkanen T, Tikkanen I, Rockell MD, Allen TJ, Johnston CI, Cooper ME, et al. Dual inhibition of neutral endopeptidase and angiotensin- converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998; 32: 778-785,
24. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal and high renin experimental hypertension. Am J Hypertens 1998; 11: 363-372.
25. Quaschning T, d'Uscio LV, Shaw S, Loscher TF. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension 2001; 37: 1108-1113.
26. Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese VM, Vesterqvist O, et al. Effects of omapatrilat on the renin-angiotensin system in salt- sensitive hypertension. Am J Hypertens 2002; 15: 557-564.
27. Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR. In vivo pharmacology of dual neutral endopeptidase/angiotensin- converting enzyme inhibitors. J Cardiovasc Pharmacol 1996; 28: 672-678.
28. Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995; 275: 745-752.
29. Fink CA, Carlson JE, McTaggart PA, Qiao Y, Webb R, Chatelain R, et al. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1996; 39: 3158-3168.
30. Fournie-Zaluski MC, Coric P, Thery V, Gonzalez W, Meudal H, Turcaud S, et al. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J Med Chem 1996; 39: 2594-2608.
31. Gonzalez W, Beslot F, Laboulandine I, Fournie-Zaluski MC, Roques BP, Michel JB. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. J Pharmacol Exp Ther 1996; 278: 573-581.
32. Ginoza M, Marques AG, Cesaretti MLR, Neves CRS, Pereira AS, Kohlmann NEB, et al. Cardiovascular and metabolic effects of the vasopeptidase inhibitor, omapatrilat in spontaneously hypertensive rats. Am J Hypertens 2000; 13: 16A.
33. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996; 94: 2131-2137.
34. Quaschning T, d'Uscio LV, Shaw S, Viswambharan H, Ruschitzka FT, Lüscher TF, et al. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalises endothelin levels in salt-induced hypertension. Nephrol Dial Transplant 2001; 16: 1176-1182.
35. d'Uscio LV, Quaschning T, Burnett JC Jr, Lüscher TF. Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition. Hypertension 2001; 37: 28-33.
36. Intengan HD, Schiffrin EL Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000; 35: 1221-1225.
37. Quaschning T, d'Uscio LV, Shaw S, Gröne HJ, Ruschitzka FT, Lüscher TF, et al. Vasopeptidase inhibition restores renovascular endothelial dysfunction and vascular hypertrophy in salt induced hypertension. J Am Soc Nephrol 2001.
38. Arnal JF, Castano C, Maupas E, Mugniot A, Darblade B, Gourdy P, et al. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis 2001; 155: 291-295.
39. Mitchell GF, Izzo JL Jr, Lacourciere Y, Ouellet JP, Neutel J, Qian C, et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002; 105: 2955-2961.
40. Lapointe N, Blais C Jr, Adam A, Parker T, Sirois MG, Gosselin H, et al. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 2002; 39: 1692-1698.
41. Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998; 64: 439-449.
42. Asmar R, Fredebohm W, Senftleber I, Chang PI, Gressin V, Sainti RK. Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring. Am J Hypertens 2000; 13: 143A.
43. Izzo JK, Herman TS, Nash S, McKenny J., Reeves RA. Omapatrilat in elderly hypertensive patients: a placebo-controlled trial. Am J Hypertens 2000; 13: 59A-60A.
44. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 38: 1342-1348.
45. Guthrie RM, Graff A, Mrocsek WJ, El Hafi SE, Reeves RA. Double-blind withdrawal of omapatrilat after long-term stable administration demonstrates persistence of antihypertensive efficacy. Am J Hypertens 2000; 13: 135A-135A.
46. Ferdinand KC, Sainti RK, Lewin AJ, Yellen GL, Barbosa JA, Kuschnir E. Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am J Hypertens 2000; 13: 138A-139A.
47. Larochelle P, Smith DHG, Ouellet J-P, Ledger GA, Reeves RA. Efficacy and safety of omapatrilat in subjects with isolated systolic hypertension. Am J Hypertens 2000; 13: 143A-144A.
48. Ruilope LM, Palatini P, Grossman E, Esposti E, Speier U, Chang PI, et al. Randomised double-blind comparison of omapatrilat with amlodipine in mild-to-moderate hypertension. Am J Hypertens 2000; 13: 134A-135A.
49. Neutel J, Weber M, Shepherd A, Pool J, Levy E, Saini R et al. Antihypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril. J Hypertens 1999; 17(suppl 3): S67.
50. Sica DA, Carretero OA, Gehr TW, Liao W. Omapatrilat pharmacokinetics and its effects on key vascular/renal markers in renal impairment. J Hypertens 1999; 17(suppl 3): S67.
51. Levine B, Maesaka JK, Smith MC, Levy EM. The safety and efficacy of omapatrilat in patients with hypertension and renal insufficiency. Am J Hypertens 2000; 13: 290A.
52. Malhotra B, Khan S, Delaney C, Ferreira IM, Hammett JL, Jemal M, et al. Effects of renal function on pharmacokinetics of omapatrilat. Clin Pharmacol Ther 1999; 65(2): 134.
53. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber MA, et al. Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. Am J Hypertens 2002; 15: 193-198.
54. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Burnett JC, Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 2001; 38: 187-191.
55. Burnett JC. Vasopeptidase inhibition. Curr Opin Nephrol Hypertens 2000; 9: 465-468.
56. Burrell LM, Droogh J, Mani V, Rockell MD, Farina NK, et al. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 2000; 13: 1110-1116.
57. Aronoff S, Saini RM, Guthrie RM, Rosenblatt S. Neurohormonal effects of vasopeptidase inhibition with omapatrilat in hypertension. J Am Coll Cardiol 2000; 35: 252A.
58. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
59. Garcia-Robles R, Villabla F, Gonzalez-Albarran O, Gomez O, Rabano A, Ruilope LM, et al. Effects of omapatrilat on blood pressure an the progression of renal failure in an experimental model of thyp II diabetes mellitus. Am J Hypertens 2000; 13: 37A.
60. Cohen DS, Mathis JE, Dotson RA, Graybill SR, Wosu NJ. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 1998; 32: 87-95.
61. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomised rats. Kidney Int 2001; 60: 715-721.
62. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12: 2051-2059.
63. Wanner C, Krane V, Metzger T, Quaschning T. Lipid changes and statins in chronic renal insufficiency and dialysis. J Nephrol 2001; 14 Suppl 4: S76-S80.
64. Hammett JL, Sica DA, Scicli AG, Carretero OA, Beierle FA, Delaney NG, et al. Omapatrilat increases key vascular/renal markers regardless of renal function. Clin Pharmacol Ther 1999; 65(2): 131.
65. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620.
66. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926.
67. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356: 608-609.
68. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Design 2004; 10(29): 3591-605.
69. Salvetti A, Versari D. Control of blood pressure in the community: an unsolved problem. Curr Pharm Design 2003; 9(29): 2375-84.
70. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Design 2004; 10(29): 3621-37.